Retinalamin plus Cortexin: optic-nerve and retinal method — RU2373904C1
Ольга Геннадьевна Гусаревич (RU), Ольга Геннадьевна Гусаревич, Анна Аркадьевна Гусаревич (RU), Анна Аркадьевна Гусаревич, Анжелла Жановна Фурсова (RU), Анжелла Жановна Фурсова · 2009 · RU2373904C1 · patent family 41476515
Published 2009-11-27.
Reported patent results
Reported findings
Visual improvement was reported in some eyes, with a persistent non-response in a blind eye.
Two illustrative eye-disease cases receiving Retinalamin, Cortexin and physical-treatment procedures.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Glaucoma case: right eye | Corrected visual acuity 0.3 → 0.5; total visual-field expansion reported as 40° | Combined care in one 76-year-old patient · After a 10-day course |
| Glaucoma case: left eye | Visual acuity remained 0 | The eye had longstanding blindness; no recovery was reported · After the course |
| Other case: left eye at discharge | Visual acuity reported as 0.2, without correction | An individual post-treatment value, not a group mean |
Two selected cases and multiple procedures cannot establish either peptide preparation’s independent effect, safety of the route, or a reliable comparative benefit.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. The method combines Retinalamin and Cortexin with physical-treatment procedures for optic-nerve or retinal disease.
Combined treatment and patent case examples do not establish either extract's independent benefit or validate a new administration route.
- Publication
- RU2373904C1 ↗ · 2009-11-27
- Earliest priority / filing
- 2008-07-08 / 2008-07-08
- Original applicant / assignee
- Ольга Геннадьевна Гусаревич
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 41476515 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of treating diseases of optic nerve and retina
Inventors: Ольга Геннадьевна Гусаревич (RU); Ольга Геннадьевна Гусаревич; Анна Аркадьевна Гусаревич (RU); Анна Аркадьевна Гусаревич; Анжелла Жановна Фурсова (RU); Анжелла Жановна Фурсова.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Combined treatment and patent case examples do not establish either extract's independent benefit or validate a new administration route.
- Two selected cases and multiple procedures cannot establish either peptide preparation’s independent effect, safety of the route, or a reliable comparative benefit.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-41476515. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Ольга Геннадьевна Гусаревич (RU), Ольга Геннадьевна Гусаревич, Анна Аркадьевна Гусаревич (RU), Анна Аркадьевна Гусаревич, Анжелла Жановна Фурсова (RU), Анжелла Жановна Фурсова. Retinalamin plus Cortexin: optic-nerve and retinal method — RU2373904C1 RU2373904C1 · patent family 41476515 2009.
Molekul research summary: https://molekul.io/research/patent-ru2373904c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Retinalamin
A retinal tissue-derived peptide preparation studied in ophthalmology. It is distinct from the short-peptide catalogue entry Normophthal.
Cortexin
A tissue-derived preparation with Russian stroke, cognitive, pediatric and other clinical reports. Study designs vary; the independent stroke review is shown alongside favorable original reports. None validates the personal WHOOP diary.